<?xml version="1.0" encoding="UTF-8"?>
<p>Nonetheless, this conventional de novo approach is still a stumbling block to many big pharmaceutical and biotechnology companies as it is an utterly time-consuming, laborious, high-risk and costly process. For instance, it usually costs an average of US$2.6 billion for approximately 17 years of development from molecule to market. Even so, only 2.01% of all drug development initiatives finally make it to the market as a successful drug [
 <xref rid="B4-viruses-12-01058" ref-type="bibr">4</xref>]. To add to this, the resource-intensive process requires high public demand to make it worth the effort as well as pressure on the industry to produce a drug that is affordable and significantly profitable for the drug producer. Research and development costs have always been a critical success factor for a new drug. Unfortunately, the number of new drugs approved per dollar invested has decreased significantly since the mid-1990s despite the enormous spending and investment in research and development [
 <xref rid="B5-viruses-12-01058" ref-type="bibr">5</xref>].
</p>
